A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors
Year: 2017
Type: review
Study design: Observational Study
Abstract: Cyclooxygenase-2 inhibitors (coxibs) are characterized by multiple molecular off-target effects and increased coronary artery disease (CAD) risk. Here, we systematically explored common variants of genes representing molecular targets of coxibs for association with CAD. Given a broad spectrum of pleiotropic effects of coxibs, our intention was to narrow potential mechanisms affecting CAD risk as we hypothesized that the affected genes may also display genomic signals of coronary disease risk. A Drug Gene Interaction Database search identified 47 gene products to be affected by coxibs. We traced association signals in 200-kb regions surrounding these genes in 84,813 CAD cases and 202,543 controls. Based on a threshold of 1 × 10−5 (Bonferroni correction for 3131 haplotype blocks), four gene loci yielded significant associations. The lead SNPs were rs7270354 (MMP9), rs4888383 (BCAR1), rs6905288 (VEGFA1), and rs556321 (CACNA1E). By additional genotyping, rs7270354 at MMP9 and rs4888383 at BCAR1 also reached the established GWAS threshold for genome-wide significance. The findings demonstrate overlap of genes affected by coxibs and those mediating CAD risk and points to further mechanisms, which are potentially responsible for coxib-associated CAD risk. The novel approach furthermore suggests that genetic studies may be useful to explore the clinical relevance of off-target drug effects.
Source: Scientific Reports
Authors: Ingrid Brænne, Christina Willenborg, Vinicius Tragante, Thorsten Kessler, Lingyao Zeng, Benedikt Reiz, Mariana Kleinecke, Simon von Ameln, Cristen J. Willer, Markku Laakso, Philipp S. Wild, Tanja Zeller, Lars Wallentin, Paul W. Franks, Veikko Salomaa, Abbas Dehghan, Thomas Meitinger, Nilesh J. Samani, Folkert W. Asselbergs, Jeanette Erdmann, Heribert Schunkert
Institutions: German Centre for Cardiovascular Research, University of Lübeck, University Medical Center Utrecht, Deutsches Herzzentrum München, Technical University of Munich, University of Michigan, University of Eastern Finland, Kuopio University Hospital, University Medical Center of the Johannes Gutenberg University Mainz, University Medical Center Hamburg-Eppendorf, Uppsala University, Lund University, Skåne University Hospital, Finnish Institute for Health and Welfare, Erasmus MC, Helmholtz Munich, Institut für Humangenetik, University of Leicester, Glenfield Hospital, NIHR Leicester Cardiovascular Biomedical Research Unit, University College London
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,690
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Deutsches Zentrum für Herz-Kreislaufforschung, National Institute for Health and Care Research, British Heart Foundation, European Commission, Deutsche Forschungsgemeinschaft, Fondation Leducq, Bundesministerium für Bildung und Forschung, Universität zu Lübeck, Novo Nordisk, Exzellenzclusters Entzündungsforschung
OpenAlex ID: W2748058077